4167 Stock Overview
A specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4167 from our risk checks.
Savior Lifetec Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$20.50 |
| 52 Week High | NT$27.80 |
| 52 Week Low | NT$18.10 |
| Beta | 0.53 |
| 11 Month Change | -5.75% |
| 3 Month Change | -10.09% |
| 1 Year Change | 6.22% |
| 33 Year Change | 4.59% |
| 5 Year Change | -0.27% |
| Change since IPO | -20.62% |
Recent News & Updates
Recent updates
Is Savior Lifetec (GTSM:4167) Using Too Much Debt?
Mar 29
Update: Savior Lifetec (GTSM:4167) Stock Gained 35% In The Last Five Years
Feb 22Savior Lifetec Corporation (GTSM:4167) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Jan 25Should You Use Savior Lifetec's (GTSM:4167) Statutory Earnings To Analyse It?
Dec 29Savior Lifetec (GTSM:4167) Seems To Use Debt Quite Sensibly
Dec 03
Shareholder Returns
| 4167 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.7% | -2.4% | -0.6% |
| 1Y | 6.2% | 6.3% | 29.2% |
Return vs Industry: 4167 matched the TW Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: 4167 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 4167 volatility | |
|---|---|
| 4167 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4167 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4167's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Freon Chen | www.saviorlifetec.com.tw/en/ |
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various products, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products.
Savior Lifetec Corporation Fundamentals Summary
| 4167 fundamental statistics | |
|---|---|
| Market cap | NT$6.51b |
| Earnings (TTM) | NT$179.84m |
| Revenue (TTM) | NT$1.26b |
36.2x
P/E Ratio5.2x
P/S RatioIs 4167 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4167 income statement (TTM) | |
|---|---|
| Revenue | NT$1.26b |
| Cost of Revenue | NT$861.13m |
| Gross Profit | NT$397.24m |
| Other Expenses | NT$217.40m |
| Earnings | NT$179.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 31.57% |
| Net Profit Margin | 14.29% |
| Debt/Equity Ratio | 0% |
How did 4167 perform over the long term?
See historical performance and comparison